Background: Acute pediatric diarrhea is one of the most common causes of morbidity and mortality worldwide and seriously affects the health of children. Previous studies have shown that pediatric Tuina, a traditional Chinese medicine therapy, has potential therapeutic benefits for acute pediatric diarrhea. However, the evidence for its effectiveness is insufficient due to the lack of high-quality clinical studies. Our aim is to evaluate the efficacy of Chinese pediatric Tuina for children aged 0-6 years with acute diarrhea.

Methods/design: This study is a randomized, double-blind, sham-controlled trial. We will include 122 children with acute diarrhea from Dongguan Kanghua Hospital in Guangdong province, China. The patients will be allocated into either the pediatric Tuina group or the sham Tuina group in a 1:1 ratio. The treatment will last for 3 days followed by an 11-day follow-up period. Both groups will receive usual care. In addition, the experimental group will receive 15-25 min of Chinese pediatric Tuina, while the control group will receive 15-25 min of sham pediatric Tuina. Both groups will receive treatments once per day, for 3 consecutive days. Primary outcome measures are diarrhea days from baseline and diarrhea times on the third day. Secondary outcome measures are the global change rating and period of days when the stool character changes to normal. Safety assessments will be monitored during each visit.

Discussion: This clinical trial is designed to evaluate the efficacy of pediatric Tuina for children with acute diarrhea. We expect results to provide solid evidence and support for pediatric Tuina as an appropriate treatment for children with acute diarrhea.

Trial Registration: ClinicalTrials.gov, NCT03005821. Registered on 29 December 2016.

Download full-text PDF

Source
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC6902472PMC
http://dx.doi.org/10.1186/s13063-019-3818-1DOI Listing

Publication Analysis

Top Keywords

pediatric tuina
32
will receive
16
chinese pediatric
12
tuina children
12
children acute
12
acute diarrhea
12
tuina
9
pediatric
9
sham-controlled trial
8
acute pediatric
8

Similar Publications

Enhancing motor function in children with cerebral palsy: A Comparative study of pediatric tuina and conventional rehabilitation.

J Bodyw Mov Ther

March 2025

Department of Rehabilitation Medicine, The First Affiliated Hospital,Jiangxi Medical College, Nanchang University,No.17 Yongwaizheng Street,Nanchang 330006,Jiangxi Province,China.

Objective: This study explores the impact of combining Pediatric Tuina (PT) with conventional rehabilitation on motor function in children diagnosed with cerebral palsy (CP).

Methods: This controlled trial involved 115 CP-affected children aged 1 month to 13 years. They were allocated into an experimental group (n = 57) receiving PT and conventional rehabilitation, and a control group (n = 58) receiving only conventional rehabilitation for three months.

View Article and Find Full Text PDF

Pediatric Tuina for the treatment of functional dyspepsia: A systematic review and meta-analysis of randomized controlled trials.

Complement Ther Med

December 2024

Division of Digestive Diseases, Department of Korean Internal Medicine, Kyung Hee University Korean Medicine Hospital, 23 Kyungheedae-ro, Dongdaemun-gu, Seoul 02447, Republic of Korea; Department of Digestive Diseases, College of Korean Medicine, Kyung Hee University, 26 Kyungheedae-ro, Dongdaemun-gu, Seoul 02447, Republic of Korea; Department of Clinical Korean Medicine, Graduate School, Kyung Hee University, 26 Kyungheedae-ro, Dongdaemun-gu, Seoul 02447, Republic of Korea. Electronic address:

Background: Functional dyspepsia (FD) is the most prevalent pediatric gastrointestinal disorder, imposing a significant burden on healthcare services and often persisting into adulthood. Tuina, a traditional manual therapy, is frequently employed in the treatment of FD. This study aimed to systematically evaluate the efficacy and safety of Tuina in treating FD in children.

View Article and Find Full Text PDF

Rationale: Koolen-De Vries syndrome (KdVS, OMIM: 612452), also known as 17q21.31 microdeletion syndrome, is an autosomal dominant genetic disease. In the study, we analyze of clinical phenotype and gene variation of a child with Koolen-De Vries syndrome, review the literature to improve the understanding of the disease.

View Article and Find Full Text PDF
Article Synopsis
  • Asfotase alfa (AA) is an FDA-approved treatment for hypophosphatasia, but there is limited data on its side effects in the real world.
  • This study analyzed 5,040 adverse events (AEs) related to AA using the U.S. FDA's Adverse Event Reporting System, identifying common issues like injection site reactions and ear/labyrinth disorders.
  • The findings suggest that while most AEs are consistent with known data, the newly identified issues warrant further investigation to improve the safety profile of AA.
View Article and Find Full Text PDF

Background: Increasing evidence has emerged for traditional, complementary and integrative medicine (TCIM) to treat COVID-19 which requires systematic summaries of the net benefits of interventions against standard care and one another. The study aims to conduct a systematic review and network meta-analysis (NMA) regarding TCIM therapies for treating mild/moderate acute COVID-19, potentially informing the WHO guideline development and clinical decision-making.

Methods And Analysis: We will search Embase, MEDLINE, Virtual Health Library on Traditional Complementary and Integrative Medicine, Cochrane Central Register of Controlled Trials, WHO's International Clinical Trials Registry Platform with additional searches of Chinese and Korean literature sources for randomised controlled trials comparing TCIM with placebo, standard care, no treatment or with an alternate type of TCIM to treat COVID-19.

View Article and Find Full Text PDF

Want AI Summaries of new PubMed Abstracts delivered to your In-box?

Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!